Helen Broadhurst

1.1k total citations
18 papers, 650 citations indexed

About

Helen Broadhurst is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Helen Broadhurst has authored 18 papers receiving a total of 650 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Pharmacology. Recurrent topics in Helen Broadhurst's work include Antibiotics Pharmacokinetics and Efficacy (6 papers), Antibiotic Resistance in Bacteria (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Helen Broadhurst is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (6 papers), Antibiotic Resistance in Bacteria (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Helen Broadhurst collaborates with scholars based in United States, United Kingdom and Spain. Helen Broadhurst's co-authors include Paul Newell, Leanne B. Gasink, J. Armstrong, John E. Mazuski, Greg Stone, Lily Llorens, Jan Pachl, Katrina Yates, Gregory G. Stone and Angela Wardman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Infectious Diseases.

In The Last Decade

Helen Broadhurst

18 papers receiving 645 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Broadhurst United States	11	428	362	252	198	114	18	650
Marie Abdallah United States	10	427 1.0×	291 0.8×	174 0.7×	159 0.8×	92 0.8×	24	660
Adam D. Lipworth United States	8	205 0.5×	73 0.2×	158 0.6×	142 0.7×	119 1.0×	19	483
Y. Valcke Belgium	11	114 0.3×	207 0.6×	205 0.8×	38 0.2×	72 0.6×	23	553
Nicole Pagani Italy	10	212 0.5×	80 0.2×	204 0.8×	140 0.7×	30 0.3×	23	422
Ana Coloma Spain	8	297 0.7×	85 0.2×	211 0.8×	138 0.7×	25 0.2×	28	519
Qiquan Wan China	15	181 0.4×	116 0.3×	272 1.1×	31 0.2×	41 0.4×	56	615
Cumhur Y. Demirkale United States	10	98 0.2×	58 0.2×	174 0.7×	125 0.6×	26 0.2×	19	488
Se Kyu Kim South Korea	9	137 0.3×	38 0.1×	259 1.0×	60 0.3×	107 0.9×	19	553
‏Mohammed ‏Khashab United States	10	113 0.3×	151 0.4×	290 1.2×	59 0.3×	55 0.5×	15	451
Silvia Terraneo Italy	15	116 0.3×	46 0.1×	178 0.7×	72 0.4×	36 0.3×	36	639

Countries citing papers authored by Helen Broadhurst

Since Specialization

Citations

This map shows the geographic impact of Helen Broadhurst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Broadhurst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Broadhurst more than expected).

Fields of papers citing papers by Helen Broadhurst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Broadhurst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Broadhurst. The network helps show where Helen Broadhurst may publish in the future.

Co-authorship network of co-authors of Helen Broadhurst

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Broadhurst. A scholar is included among the top collaborators of Helen Broadhurst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Broadhurst. Helen Broadhurst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Vansteenkiste, Johan, Jarushka Naidoo, Corinne Faivre‐Finn, et al.. (2024). Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC. JTO Clinical and Research Reports. 5(3). 100638–100638. 6 indexed citations

Besse, Benjamin, Gilberto de Castro, Enriqueta Felip, et al.. (2023). LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.. Journal of Clinical Oncology. 41(16_suppl). TPS9161–TPS9161. 3 indexed citations

Naidoo, Jarushka, Johan Vansteenkiste, Corinne Faivre‐Finn, et al.. (2022). Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer. 166. 84–93. 16 indexed citations

Xie, Mingchao, Helen Broadhurst, Zhongwu Lai, et al.. (2022). Abstract CT024: Durvalumab (D) + platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN. Cancer Research. 82(12_Supplement). CT024–CT024. 17 indexed citations

Paz‐Ares, Luis, Yuanbin Chen, Niels Reinmuth, et al.. (2021). LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. Annals of Oncology. 32. S1338–S1338. 8 indexed citations

Reinmuth, Niels, Marina Chiara Garassino, Dmytro Trukhin, et al.. (2021). P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN. Journal of Thoracic Oncology. 16(3). S500–S500. 5 indexed citations

Cheng, Karen, Paul Newell, Joseph W. Chow, et al.. (2020). Safety Profile of Ceftazidime–Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme. Drug Safety. 43(8). 751–766. 18 indexed citations

Faivre‐Finn, Corinne, David R. Spigel, Suresh Senan, et al.. (2020). Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). Lung Cancer. 151. 30–38. 31 indexed citations

Naidoo, Jarushka, Johan Vansteenkiste, Corinne Faivre‐Finn, et al.. (2020). Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).. Journal of Clinical Oncology. 38(15_suppl). 9048–9048. 1 indexed citations

10.

Chen, Yuanbin, Luis Paz‐Ares, Mikhail Dvorkin, et al.. (2020). First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.. Journal of Clinical Oncology. 38(15_suppl). 9068–9068. 12 indexed citations

11.

Bradley, John S., Helen Broadhurst, Karen Cheng, et al.. (2019). Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial. The Pediatric Infectious Disease Journal. 38(8). 816–824. 49 indexed citations

12.

Bradley, John S., Emmanuel Roilides, Helen Broadhurst, et al.. (2019). Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial. The Pediatric Infectious Disease Journal. 38(9). 920–928. 56 indexed citations

13.

Raben, David, Andreas Rimner, Suresh Senan, et al.. (2019). Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC). International Journal of Radiation Oncology*Biology*Physics. 105(3). 683–683. 44 indexed citations

14.

Nichols, Wright W., Gregory G. Stone, Paul Newell, et al.. (2018). Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 62(11). 28 indexed citations

15.

Stone, Gregory G., Paul Newell, Leanne B. Gasink, et al.. (2018). Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. Journal of Antimicrobial Chemotherapy. 73(9). 2519–2523. 65 indexed citations

16.

Mazuski, John E., Leanne B. Gasink, J. Armstrong, et al.. (2016). Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clinical Infectious Diseases. 62(11). 1380–1389. 287 indexed citations

17.

Stone, Gregory G., Leanne B. Gasink, Paul Newell, et al.. (2016). Efficacy of Ceftazidime-Avibactam against Multi-Drug Resistant Enterobacteriaceae and Pseudomonas aeruginosa from the Phase 3 Clinical Trial Program. Open Forum Infectious Diseases. 3(suppl_1). 1 indexed citations

18.

Edeki, Timi, et al.. (2014). Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume. British Journal of Clinical Pharmacology. 78(6). 1291–1297. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact